All Drug Development articles – Page 11
-
NewsTargeting EZH2 may prevent triple-negative breast cancer spread
A new study has revealed that the enzyme EZH2 triggers abnormal cell division that fuels metastasis, and blocking this enzyme with existing drugs could restore normal cell behaviour to stop cancer from spreading.
-
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
-
NewsCloneSeq-SV: new blood test tracks ovarian cancer recurrence
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
-
NewsNew CAR T therapy targets solid tumours safely and effectively
USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
-
ArticleFast-tracking advanced therapies without compromising regulatory success
Early planning for potency CQAs, comparability and evolving global regulations can set advanced therapies on the fastest path to approval. Dr Christian Schneider shares how to prepare from the start to accelerate development without compromising the evidence regulators expect.
-
NewsSenolytic drug combo boosts cancer immunotherapy and reduces side effects
Researchers have discovered that targeting immune cell ageing can overcome resistance to head and neck cancer treatment.
-
ArticleFrom data to therapy: emerging tech driving cancer drug discovery
Multiomics, AI and liquid biopsies are giving researchers real-time insight into tumour biology and enabling more personalised cancer therapies. Find out how these technologies are advancing biomarker discovery, improving patient stratification, and guiding the design of new treatments.
-
NewsProtecting bones from cancer damage: targeting the UPR pathway
New research highlights how cancer hijacks the unfolded protein response (UPR) in bone cells – potentially allowing for the development of therapies that target this pathway to prevent fractures.
-
ArticleInside Zasocitinib: a new model for TYK2 inhibition in immune-mediated diseases
Zasocitinib is a highly selective, investigational TYK2 inhibitor developed to target immune-mediated diseases with fewer off-target effects than traditional JAK inhibitors. This article explores its mechanism, selectivity data and clinical progress.
-
NewsThe road to safer painkillers: the role of the EP2 receptor
NYU researchers have identified a receptor in prostaglandins that triggers pain without affecting inflammation – which could lead to safer, more targeted pain treatments.
-
NewsMarine sponges could hold the key to new Leishmaniasis treatments
Japanese researchers have discovered potent new compounds from marine sponges that could transform the treatment of leishmaniasis – a neglected tropical disease affecting millions worldwide.
-
ArticleThe science behind the systematic discovery of molecular glues
For decades, molecular glues have been stumbled upon rather than designed. A new scientific approach is now changing that – expanding what is considered druggable.
-
ArticleOvercoming barriers to oncology combination therapies in the UK and EU
Colleagues at IQVIA discuss ways to expedite positive HTA outcomes for innovative combination therapies, alleviating the bottlenecks inherent in the current system.
-
NewsGut probiotics could offer relief for sickle cell disease pain
A new study from UT Dallas and the Medical College of Wisconsin links chronic sickle cell disease pain to gut bacteria – identifying Akkermansia muciniphila as a potential target for new probiotic or microbiome-based therapies.
-
ArticleWhy scientists are targeting the gut to treat peanut allergy
A new oral immunotherapy could change how peanut allergy is treated, targeting the gut to retrain the immune system and reduce the risk of life-threatening reactions. INP20’s nanoparticle technology promises a safer, more precise approach that could replace lifelong avoidance with lasting tolerance.
-
NewsRegistration for ELRIG’s Drug Discovery 2025 closes on 30 September
Registration for ELRIG’s Drug Discovery 2025 will close on 30 September. The free to attend conference, held on 21–22 October in Liverpool, will bring together thousands of scientists, exhibitors and expert speakers.
-
NewsNovltex: new antibiotic targets antimicrobial resistance
Scientists at the University of Liverpool have discovered Novltex, a new class of antibiotics that shows potent activity against deadly multidrug-resistant bacteria such as MRSA.
-
ArticlePDX models are back – and they’re exposing what cell lines missed
As cancer drugs continue to fail in translation, researchers are turning back to patient-derived xenograft (PDX) models – this time with better science. Could they be the missing link between the lab and the clinic?
-
NewsNew obesity drug RES-010 targets metabolism to prevent weight regain
A first-in-class obesity drug, presented at the European Association for the Study of Diabetes meeting in Vienna, aims to reprogramme metabolism rather than suppress appetite – offering the potential for long-lasting weight loss without regain.
-
NewsNew therapies boost deep brain stimulation accuracy in epilepsy
In a new study, researchers have discovered that deep brain stimulation targeting the centromedian nucleus could help patients with drug-resistant epilepsy improve seizure control.